Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PROC | P04070 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL6244439 | 0.98 | MME (0.32) | MMEMAPTITGB3ITGA2BCYP2C19 | |
| SCHEMBL6864504 | 0.98 | MME (0.33) | MMEITGB3ITGA2BF2PROC | |
| SCHEMBL22529222 | 0.92 | CYP4F2 (0.31) | ITGB3ITGA2B | |
| SCHEMBL6676794 | 0.86 | MAPT (0.37) | MAPTITGB3ITGA2BEPHX1ALDH1A1 | |
| SCHEMBL3525418 | 0.86 | CA12 (0.42) | MAPTEPHX1ALDH1A1L3MBTL1CA12 | |
| SCHEMBL7431988 | 0.79 | MAPT (0.40) | MAPTEPHX1ALDH1A1L3MBTL1CA12 | |
| SCHEMBL7437999 | 0.77 | MAPT (0.38) | MAPTALDH1A1L3MBTL1CA12CA2 | |
| SCHEMBL1696853 | 0.77 | CA12 (0.41) | CA12CA2CA14 | |
| SCHEMBL27175299 | 0.77 | CTSL (0.46) | CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL5359677 | 0.76 | MAPT (0.35) | MAPTEPHX1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920093-B2 | Dimeric IAP inhibitors | TetraLogic Birinapant UK Ltd. (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20160355547-A1 | Dimeric IAP Inhibitors | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160052965-A1 | Dimeric IAP Inhibitors | TetraLogic Birinapant UK Ltd. (GB) | 2016-02-25 | — | — | US | disclosed |
| US-9187490-B2 | Dimeric IAP inhibitors | TetraLogic Birinapant UK Ltd. (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20140329823-A1 | Dimeric IAP Inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8822525-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| EP-1851200-B1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20130289042-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-8497297-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-30 | — | — | US | disclosed |
| EP-1644342-B1 | Arylpyrimidines useful for the treatment of sex hormone-related conditions such as endometriosis, prostate cancer and the like | NEUROCRINE BIOSCIENCES INC (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2002008244-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008187-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| US-20010031858-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
| WO-2001055175-A2 | PROCESS FOR THE PREPARATION OF ACETYL-AMIDINIOPHENYLALANYL-CYCLOHEXYLGLYCYL-PYRIDINIOALANINAMIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-02 | — | — | WO | disclosed |
| EP-0647629-B1 | Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-07-07 | — | — | EP | disclosed |
| US-5744487-A | PROTEASE INHIBITORS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-04-28 | — | — | US | disclosed |
| US-5523455-A | PREPARED USING A NAPHTHYLHYDRAZINE CHEMICAL INTERMEDIATE | SANOFI (FR) | 1996-06-04 | — | — | US | disclosed |
| US-5502059-A | DOPAMINERGIC DYSFUNCTION DISORDERS | SANOFI (FR) | 1996-03-26 | — | — | US | disclosed |
| EP-0669317-A1 | Prolineamide derivatives | Mitsubishi Chemical Corporation (JP) | 1995-08-30 | — | — | EP | disclosed |
| EP-0647629-A1 | Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329823-A1 | Dimeric IAP Inhibitors | BIRC2, XIAP, BIRC5 | MME 2750/4885MAPT 3849/4885ITGB3 4676/4885 |
| US-20160052965-A1 | Dimeric IAP Inhibitors | BIRC2, XIAP, BIRC5 | MME 2750/4885MAPT 3849/4885ITGB3 4676/4885 |
| US-20160355547-A1 | Dimeric IAP Inhibitors | BIRC2, XIAP, BIRC5 | MME 2750/4885MAPT 3849/4885ITGB3 4676/4885 |
| US-20010031858-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SERPINC1, F12, F11 | MME 634/4885MAPT 4707/4885ITGB3 1765/4885 |
| US-20130289042-A1 | DIMERIC IAP INHIBITORS | BIRC2, XIAP, BIRC5 | MME 2750/4885MAPT 3849/4885ITGB3 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.